secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001493152-23-000900
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo: Phase 2 data show ANEB-001 reduces THC effects; cash $16M runway into 2024
--------------------------------------------------------------------------------

- Preliminary data: single 10 mg ANEB-001 reversed key psychotropic effects of 30 mg THC, including feeling high and body sway.
- Delayed dosing of ANEB-001 (1 hour after THC) rapidly reversed pre-existing effects.
- Full PK, PD, and safety data expected by end of 1Q2023; FDA End of Phase 2A meeting targeted H1 2023.
- Cash of $16M as of Dec 31, 2022 provides runway into 2024.
- No serious adverse events; 134 subjects enrolled in Parts A and B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/0001493152-23-000900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223000900/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer